Wall Street Analysts Think Humacyte, Inc. (HUMA) Is a Good Investment: Is It? [Yahoo! Finance]
Humacyte, Inc. (HUMA)
Company Research
Source: Yahoo! Finance
Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though? Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Humacyte, Inc. (HUMA). Humacyte, Inc. currently has an average brokerage recommendation (ABR) of 1.50, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by eight brokerage firms. An ABR of 1.50 approximates between Strong Buy and Buy. Of the eight recommendations that derive the current ABR, six are Strong Buy, representing 75% of all recommendations. Brokerage Recommendation Trends for HUMA Broker Rating Breakdown Chart for HUMA Check price target & stock forecast for Humacyte, Inc. here The ABR suggests buying Humacyte, Inc., but making an investment decision solely on the basis of
Show less
Read more
Impact Snapshot
Event Time:
HUMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HUMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HUMA alerts
High impacting Humacyte, Inc. news events
Weekly update
A roundup of the hottest topics
HUMA
News
- Humacyte To Announce 2025 Fourth Quarter and Year End Financial Results and Provide Business Update on March 27, 2026GlobeNewswire
- Humacyte, Inc. (HUMA) Submits Marketing Authorization Application in Israel for Symvess [Yahoo! Finance]Yahoo! Finance
- Humacyte Receives Symvess® Purchase Commitment for Clinical Evaluation and Outreach Program in the Kingdom of Saudi ArabiaGlobeNewswire
- Humacyte, Inc. Announces Pricing of $20 Million Registered Direct Offering of Common StockGlobeNewswire
- Humacyte (HUMA) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $25.00 price target on the stock.MarketBeat
HUMA
Earnings
- 11/12/25 - Beat
HUMA
Sec Filings
- 3/19/26 - Form 8-K
- 3/19/26 - Form 424B3
- 3/19/26 - Form 8-K
- HUMA's page on the SEC website